Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed) | RFA AI 20 077

Opportunity Information: Apply for RFA AI 20 077

The Immune Development in Early Life (IDEaL) funding opportunity (RFA-AI-20-077) is a National Institutes of Health (NIH) cooperative agreement program (U01) designed to support research that explains how the immune system is established, matures, and is maintained from birth through childhood (up to, but not including, age 18). The central aim is to move beyond descriptive observations and instead define the underlying mechanisms that shape immune development over time, including how early-life exposures influence immune function and long-term immune outcomes. Although the projects may involve human participants and pediatric populations, the announcement is explicitly labeled "Clinical Trial Not Allowed," meaning applicants are expected to propose mechanistic and developmental studies rather than interventional clinical trials that test efficacy or outcomes of a treatment.

A major emphasis of the program is understanding how exposure to microbes and other environmental inputs alters immune ontogeny. This includes both pathogenic microbes (those that cause disease) and non-pathogenic microbes (such as members of the normal microbiota), as well as immune-shaping events like vaccination against infectious diseases. The announcement also highlights non-infectious exposures that are highly relevant to childhood immune programming, including allergens and environmental pollutants, with an interest in how these exposures affect immune trajectories, immune regulation, and functional immune responses during critical windows of development. The overall vision is that early life is a uniquely sensitive period for immune education, and that mapping the mechanisms at play can clarify why children differ from adults in susceptibility to infection, vaccine responsiveness, allergy development, and other immune-mediated conditions.

Another defining feature of IDEaL is its collaborative structure. The program is intended to bring together expertise across immunology, neonatology, pediatrics, microbiology, and systems biology, reflecting the idea that childhood immune development is best tackled with interdisciplinary teams and integrated data approaches. In practice, this points toward projects that combine clinical insight into pediatric populations with advanced immunologic profiling, microbial community characterization, and computational or systems-level analyses that can connect exposures to immune pathways and developmental outcomes. Because the award mechanism is a cooperative agreement (U01), awardees should generally expect substantial scientific involvement from NIH program staff compared to more investigator-driven grant types, often with an emphasis on coordination, shared standards, and collaborative progress toward program goals.

The program is ultimately positioned as foundational research with a strong translational payoff. The knowledge generated is expected to inform the design of improved vaccines and immunotherapies tailored to pediatric biology, and to support strategies to prevent or treat immune-mediated diseases that begin or are shaped in childhood. By clarifying what "normal" immune development looks like, what factors perturb it, and which mechanisms drive durable changes, the IDEaL program aims to strengthen the evidence base needed to protect a particularly vulnerable population during a period when immune defenses and immune regulation are still being built.

From an administrative and eligibility standpoint, this is a discretionary federal funding opportunity administered by NIH, listed under CFDA numbers 93.113 and 93.855, with an activity focus in health and environment. The opportunity was posted January 12, 2021, with an original closing date of June 18, 2021. The award ceiling is listed as $500,000. A wide range of applicants are eligible, including state, county, city/township, and special district governments; independent school districts; public and state-controlled and private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (outside of higher education); for-profit organizations other than small businesses as well as small businesses; and other entities. The announcement also explicitly calls out additional eligible applicant types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations).

• The National Institutes of Health in the environment, health sector is offering a public funding opportunity titled "Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113, 93.855.
• This funding opportunity was created on 2021-01-12.
• Applicants must submit their applications by 2021-06-18. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AI 20 077

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: